These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 33131688)

  • 1. Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies.
    Xie W; Huang H; Xiao S; Fan Y; Deng X; Zhang Z
    Autoimmun Rev; 2020 Dec; 19(12):102687. PubMed ID: 33131688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
    Tison A; Quéré G; Misery L; Funck-Brentano E; Danlos FX; Routier E; Robert C; Loriot Y; Lambotte O; Bonniaud B; Scalbert C; Maanaoui S; Lesimple T; Martinez S; Marcq M; Chouaid C; Dubos C; Brunet-Possenti F; Stavris C; Chiche L; Beneton N; Mansard S; Guisier F; Doubre H; Skowron F; Aubin F; Zehou O; Roge C; Lambert M; Pham-Ledard A; Beylot-Barry M; Veillon R; Kramkimel N; Giacchero D; De Quatrebarbes J; Michel C; Auliac JB; Gonzales G; Decroisette C; Le Garff G; Carpiuc I; Vallerand H; Nowak E; Cornec D; Kostine M;
    Arthritis Rheumatol; 2019 Dec; 71(12):2100-2111. PubMed ID: 31379105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.
    Yu Y; Zhou Y; Zhang X; Tan K; Zheng J; Li J; Cui H
    Front Oncol; 2022; 12():934093. PubMed ID: 35912183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preexisting autoimmune disease is a risk factor for immune-related adverse events: a meta-analysis.
    Yamaguchi A; Saito Y; Okamoto K; Narumi K; Furugen A; Takekuma Y; Sugawara M; Kobayashi M
    Support Care Cancer; 2021 Dec; 29(12):7747-7753. PubMed ID: 34164739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease.
    Lopez-Olivo MA; Kachira JJ; Abdel-Wahab N; Pundole X; Aldrich JD; Carey P; Khan M; Geng Y; Pratt G; Suarez-Almazor ME
    Eur J Cancer; 2024 Aug; 207():114148. PubMed ID: 38834015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis.
    Liu X; Li S; Ke L; Cui H
    BMC Cancer; 2024 Apr; 24(1):490. PubMed ID: 38632528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review.
    Abdel-Wahab N; Shah M; Lopez-Olivo MA; Suarez-Almazor ME
    Ann Intern Med; 2018 Jan; 168(2):121-130. PubMed ID: 29297009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
    Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
    Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
    Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
    Front Immunol; 2021; 12():730320. PubMed ID: 34646270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis.
    Cai Q; Huo GW; Zhu FY; Yue P; Yuan DQ; Chen P
    Hum Vaccin Immunother; 2022 Dec; 18(7):2145102. PubMed ID: 36471629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Immune Checkpoint Inhibitors in Cancer Patients and Preexisting Autoimmune Disease: A Systematic Review and Meta-Analysis in Non-Small-Cell Lung Cancer.
    Aung WY; Lee CS; Morales J; Rahman H; Seetharamu N
    Clin Lung Cancer; 2023 Nov; 24(7):598-612. PubMed ID: 37328320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus.
    Hilder R; Tsai K; Quandt Z; Isaacs D; Drakaki A; Xing Y; In GK; Angell TE; Lechner MG
    Front Endocrinol (Lausanne); 2023; 14():1242830. PubMed ID: 38027216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
    Front Immunol; 2021; 12():760737. PubMed ID: 34925331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Landscape of immune checkpoint inhibitor-related adverse events in Chinese population.
    Li L; Li G; Rao B; Dong AH; Liang W; Zhu JX; Qin MP; Huang WW; Lu JM; Li ZF; Wu YZ
    Sci Rep; 2020 Sep; 10(1):15567. PubMed ID: 32968172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases.
    Pizuorno Machado A; Shatila M; Liu C; Wang J; Altan M; Zhang HC; Thomas A; Wang Y
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6341-6350. PubMed ID: 36752908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of immune checkpoint inhibitors in patients with preexisting autoimmune disorders.
    Kumar R; Chan A; Bandikatla S; Ranjan S; Ngo P
    Curr Probl Cancer; 2022 Aug; 46(4):100864. PubMed ID: 35671576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis.
    Efuni E; Cytryn S; Boland P; Niewold TB; Pavlick A; Weber J; Sandigursky S
    J Clin Rheumatol; 2021 Oct; 27(7):267-271. PubMed ID: 31977647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases.
    Reid P; Sandigursky S; Song J; Lopez-Olivo MA; Safa H; Cytryn S; Efuni E; Buni M; Pavlick A; Krogsgaard M; Abu-Shawer O; Altan M; Weber JS; Rahma OE; Suarez-Almazor ME; Diab A; Abdel-Wahab N
    Oncoimmunology; 2023; 12(1):2261264. PubMed ID: 38126033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Non-small Cell Lung Cancer and Preexisting Interstitial Lung Diseases: A Systematic Review and Meta-analysis.
    Zhang M; Fan Y; Nie L; Wang G; Sun K; Cheng Y
    Chest; 2022 Jun; 161(6):1675-1686. PubMed ID: 35026298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology.
    Hoa S; Laaouad L; Roberts J; Ennis D; Ye C; Al Jumaily K; Pope J; Nevskaya T; Saltman A; Himmel M; Rottapel R; Ly C; Colmegna I; Fifi-Mah A; Maltez N; Tisseverasinghe A; Hudson M; Jamal S
    Cancer Immunol Immunother; 2021 Aug; 70(8):2197-2207. PubMed ID: 33471137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.